Page 1

PRESS RELEASE Lyon , October 26 , 2021 ADOCIA innovative medicine for everyone , everywhere Adocia announces 2021 third quarter financial results and a financing of € 7 million through the issuance of convertible bonds subscribed by European investors and ordinary shares subscribed by Gérard Soula , Adocia co - founder • A cash position of € 14.3 million as of September 30th , 2021 • In addition , a financing of € 7 million completed today and composed of : € 6 million through the issuance of convertible bonds subscribed by European investors € 1 million through the issuance of 107 992 new ordinary shares to be subscribed by Gerard Soula at a price per share of € 9.26 calculated on the basis of the last three trading days , with no discount - 8:30 pm CEST Adocia ( Euronext Paris : FR0011184241 ADOC ) , a clinical - stage biopharmaceutical company specialized in the development of innovative formulations of proteins and peptides for the treatment of diabetes and other metabolic diseases announced today its third quarter financial results as well as the completion , today , of a financing of EUR 7 million . " Results for the quarter are in line with our operating plan , with a cash burn for the first nine months of 2021 of EUR 13.8 million " , commented Valérie Danaguezian , Chief Financial Officer of Adocia . " Combined with our current cash position , this EUR 7 million financing strengthens our financial means without taking into account possible new partnerships . " " I am very pleased with Vester Finance's participation in this financing operation which will allow us to accelerate the development of our most recent innovations while pushing ahead with partnerships discussions for our flagship products . It is with confidence that I have personally participated in this financing " , said Gerard Soula , Chairman and Chief Executive Office of Adocia . 1/7